Sunday, February 26, 2017 9:48:25 PM
Annual US sales for Esmya are projected from $286M to $1B, depending on competition and label restrictions. If Proellex proves to be 50% more effective and length of treatment is 50% longer, it stands to reason Proellex could capture more than 50% of that market, even with Esmya's first mover advantage. Even if sales are just $500M and if Proellex could capture $300M and a company's value is >5 times revenue, that puts value of Proellex at a possible $1.5B upon approval. With just 25M shares, that's a value of $60 per share. Question is, how much could Rprx bring on the open market for P2 data and FDA P3 guidance for Proellex and Androxal, because they don't have the cash to get both drugs to approval.
Allergan’s uterine fibroids prospect, Esmya, has racked up more data that’ll support the FDA filing it expects to make later this year. But the med will still face some market hurdles that could thwart the major sales potential its maker expects.
Tuesday, the Dublin pharma and partner Gedeon Richter rolled out phase 3 results showing their candidate had topped placebo at staving off uterine bleeding. The data follow up on earlier phase 3 results that dropped last May and make Esmya the first oral uterine fibroids therapy to prove safe and effective two U.S. pivotal studies, Allergan said.
Now, the companies are turning their attention to an FDA filing set to drop in the second half of this year. But the way Barclays analyst Doug Tsao sees it, thanks to “potential labeling limitations” and the “competitive landscape,” the relative market size for Esmya “remains uncertain,” he wrote in a Tuesday note to clients.
Uterine fibroids are the most common benign tumors in women of childbearing age, he noted, amounting to “an incremental 600,000 hysterectomies per year.” AbbVie’s Lupron is also an option for patients, though the “pseudo-menopausal” state it brings on comes along with “burdensome” side effects and symptoms.
Still, the FDA could restrict Esmya’s patient population only to those women eligible for surgery, and it also still unclear whether regulators will restrict dosing of the once-daily treatment to two cycles—both of which could limit the U.S. potential that Allergan pegs between $500 million and $1 billion.
Analysts are less optimistic, Tsao wrote, citing a $286 million peak sales consensus estimate from First Order Analytics. And that’s in part because AbbVie and partner Neurocrine have a competitor on the rise in elagolix, which is currently in phase 3.
Regardless, an FDA green light for Esmya would be a win for Allergan, whose buyer Watson has been here with the med before. The company went after a U.S. approval for Esyma in 2013, but it withdrew a phase 3 study before completion. Allergan replaced the study with the two current phase 3 studies after negotiations with the FDA.
That’s not to say Allergan hasn't already profited stateside off the compound. The company marketed Esmya’s active ingredient as contraception pill Ella in the U.S. before selling those rights to HRA Pharma.
Recent RPRX News
- Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement • GlobeNewswire Inc. • 09/03/2024 09:14:32 PM
- Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement • GlobeNewswire Inc. • 09/03/2024 09:06:29 PM
- Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference • GlobeNewswire Inc. • 08/28/2024 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:20:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:19:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:17:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 01:02:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:20:53 AM
- Royalty Pharma Reports Second Quarter 2024 Results • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:04:01 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/29/2024 08:30:11 PM
- Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital • GlobeNewswire Inc. • 07/24/2024 12:30:00 PM
- Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 • GlobeNewswire Inc. • 07/19/2024 12:15:00 PM
- Royalty Pharma Declares Third Quarter 2024 Dividend • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:03:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:58:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:06:32 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/04/2024 09:12:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:57:02 PM
- Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 08:15:00 PM
- Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes • GlobeNewswire Inc. • 06/03/2024 09:15:27 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 06/03/2024 08:59:57 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/03/2024 01:13:40 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 06/03/2024 12:39:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 09:25:01 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM